If approved, the GSK’s RSV will be the first available in Japan for the vaccine group.
RSV was the first vaccine approved in Japan for adults for the prevention of RSV disease, and increased risk for people over 50 years of age and for serious RSV disease. The company said that regulatory presentations to expand the signs of RSV vaccine continue in other geographies including the US and Europe.
For such health news, go to RTTNEWS.COM.
The idea and opinion expressed here are the idea and opinion of the author and not necessarily Nasdac, Inc.
